This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n20http://purl.org/net/nknouf/ns/bibtex#
n13http://linked.opendata.cz/resource/domain/vavai/projekt/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
n5https://schema.org/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023752%3A_____%2F13%3A43914450%21RIV14-MSM-00023752/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n21http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023752%3A_____%2F13%3A43914450%21RIV14-MSM-00023752
rdf:type
skos:Concept n6:Vysledek
rdfs:seeAlso
https://www.novapublishers.com/catalog/product_info.php?products_id=10607
dcterms:description
Cognitive deficit represents the core impairment in schizophrenia that fundamentally affects course and functional outcome of illness. Thus far, generally held views claim that conventional antipsychotics are less effective in cognitive remediation; furthermore, cognition may be worsened by the adjuvant anticholinergic medication used to alleviate from side effects. However, several earlier and recent reports indicated that a low dosage of typical antipsychotics may possess procognitive properties. Unequivocally positive effects of virtually all second-generation antipsychotics in remediation of a cognitive deficit have been shown in both individual studies and meta-analyses. The key role in cognition is played by dopamine activity in the prefrontal cortex. Dopamine action is mediated through D1 receptors, as evidenced by the improvement of cognitive performance following administration of D1 agonists. Stimulation of dopamine neurotransmission is rate-limited: low doses enhance cognition whereas higher doses may cause cognitive impairments. Dopamine activity can be also modulated indirectly, via serotonin receptor system, either with 5-HT1a agonists or 5-HT2 antagonists. Cognitive deficit represents the core impairment in schizophrenia that fundamentally affects course and functional outcome of illness. Thus far, generally held views claim that conventional antipsychotics are less effective in cognitive remediation; furthermore, cognition may be worsened by the adjuvant anticholinergic medication used to alleviate from side effects. However, several earlier and recent reports indicated that a low dosage of typical antipsychotics may possess procognitive properties. Unequivocally positive effects of virtually all second-generation antipsychotics in remediation of a cognitive deficit have been shown in both individual studies and meta-analyses. The key role in cognition is played by dopamine activity in the prefrontal cortex. Dopamine action is mediated through D1 receptors, as evidenced by the improvement of cognitive performance following administration of D1 agonists. Stimulation of dopamine neurotransmission is rate-limited: low doses enhance cognition whereas higher doses may cause cognitive impairments. Dopamine activity can be also modulated indirectly, via serotonin receptor system, either with 5-HT1a agonists or 5-HT2 antagonists.
dcterms:title
Pharmacological management of cognitive deficit in schizophrenia Pharmacological management of cognitive deficit in schizophrenia
skos:prefLabel
Pharmacological management of cognitive deficit in schizophrenia Pharmacological management of cognitive deficit in schizophrenia
skos:notation
RIV/00023752:_____/13:43914450!RIV14-MSM-00023752
n6:predkladatel
n7:ico%3A00023752
n4:aktivita
n18:P
n4:aktivity
P(1M0517)
n4:dodaniDat
n17:2014
n4:domaciTvurceVysledku
n12:1965247
n4:druhVysledku
n15:C
n4:duvernostUdaju
n21:S
n4:entitaPredkladatele
n19:predkladatel
n4:idSjednocenehoVysledku
96002
n4:idVysledku
RIV/00023752:_____/13:43914450
n4:jazykVysledku
n11:eng
n4:klicovaSlova
glutamate; norepinephrine; dopamine; antipsychotics; cognition; schizophrenia
n4:klicoveSlovo
n16:glutamate n16:dopamine n16:schizophrenia n16:antipsychotics n16:cognition n16:norepinephrine
n4:kontrolniKodProRIV
[6131C84BAE89]
n4:mistoVydani
New York
n4:nazevEdiceCisloSvazku
Psychology Research Progress
n4:nazevZdroje
Cognitive Deficit in Mental and Neurological Disorders
n4:obor
n8:FL
n4:pocetDomacichTvurcuVysledku
1
n4:pocetStranKnihy
454
n4:pocetTvurcuVysledku
1
n4:projekt
n13:1M0517
n4:rokUplatneniVysledku
n17:2013
n4:tvurceVysledku
Mohr, Pavel
s:numberOfPages
13
n20:hasPublisher
Nova Science Publishers
n5:isbn
978-1-60741-957-0